Literature DB >> 18377828

The role of PET-CT in the management of patients with advanced cancer of the head and neck.

June Corry1, Danny Rischin, Rodney J Hicks, Lester J Peters.   

Abstract

The development of functional imaging using positron emission tomography (PET) has been a major advancement in clinical oncology. In addition, the integration of functional imaging with CT anatomical imaging (PET-CT) has dramatically increased the clinical applicability of PET. This review discusses the current role of PET-CT in head and neck cancer, focusing on its role in staging, detection of unknown primaries, radiotherapy planning, assessment of treatment response, and biological characterization of disease. We also demonstrate why PET-CT should be an integral part of modern management of head and neck cancer.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18377828     DOI： 10.1007/s11912-008-0023-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  49 in total

1.  Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer.

Authors:  Arnold C Paulino; Mary Koshy; Rebecca Howell; David Schuster; Lawrence W Davis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

2.  Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose.

Authors:  K M Greven; J W Keyes; D W Williams; W F McGuirt; W T Joyce
Journal:  Cancer       Date:  1999-07-01       Impact factor: 6.860

3.  Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study.

Authors:  Jørgen Johansen; Annika Eigtved; Christian Buchwald; Sune A Theilgaard; Hanne S Hansen
Journal:  Laryngoscope       Date:  2002-11       Impact factor: 3.325

4.  Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma.

Authors:  R J Wong; D T Lin; H Schöder; S G Patel; M Gonen; S Wolden; D G Pfister; J P Shah; S M Larson; D H Kraus
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

5.  pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.

Authors:  Bernd Gagel; Patrick Reinartz; Ercole Dimartino; Michael Zimny; Michael Pinkawa; Payam Maneschi; Sven Stanzel; Kurt Hamacher; Heinz H Coenen; Michael Westhofen; Ulrich Büll; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2004-10       Impact factor: 3.621

Review 6.  Whole-body imaging with PET/MRI.

Authors:  J Gaa; E J Rummeny; M D Seemann
Journal:  Eur J Med Res       Date:  2004-06-30       Impact factor: 2.175

7.  The occult head and neck primary: to treat or not to treat?

Authors:  K Sinnathamby; L J Peters; C Laidlaw; P G Hughes
Journal:  Clin Oncol (R Coll Radiol)       Date:  1997       Impact factor: 4.126

8.  Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion.

Authors:  Heiko Schöder; Henry W D Yeung; Mithat Gonen; Dennis Kraus; Steven M Larson
Journal:  Radiology       Date:  2004-02-27       Impact factor: 11.105

9.  Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.

Authors:  Athanassios Argiris; Kerstin M Stenson; Bruce E Brockstein; Bharat B Mittal; Harold Pelzer; Merrill S Kies; Prathima Jayaram; Louis Portugal; Barry L Wenig; Fred R Rosen; Daniel J Haraf; Everett E Vokes
Journal:  Head Neck       Date:  2004-05       Impact factor: 3.147

10.  PET tracer development--a tale of mice and men.

Authors:  Rodney J Hicks; Donna Dorow; Peter Roselt
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909
View more
  5 in total

1.  [Radiological normal anatomy of the larynx and pharynx and imaging techniques].

Authors:  S F Nemec; C R Krestan; I M Noebauer-Huhmann; M Formanek; J Frühwald; P Peloschek; F Kainberger; C Czerny
Journal:  Radiologe       Date:  2009-01       Impact factor: 0.635

Review 2.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.

Authors:  Richard L Wahl; Joseph M Herman; Eric Ford
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

Review 3.  Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site - current status and challenges.

Authors:  Jens Müller von der Grün; Aykut Tahtali; Shahram Ghanaati; Claus Rödel; Panagiotis Balermpas
Journal:  Radiat Oncol       Date:  2017-05-10       Impact factor: 3.481

4.  MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.

Authors:  George Fountzilas; Anna Kalogera-Fountzila; Sophia Lambaki; Ralph M Wirtz; Angelos Nikolaou; Georgia Karayannopoulou; Mattheos Bobos; Vassiliki Kotoula; Samuel Murray; Alexandros Lambropoulos; Gerasimos Aravantinos; Konstantinos Markou; Eleni Athanassiou; Despina Misailidou; Konstantine T Kalogeras; Demosthenis Skarlos
Journal:  J Oncol       Date:  2009-12-29       Impact factor: 4.375

Review 5.  Quo vadis radiotherapy? Technological advances and the rising problems in cancer management.

Authors:  Barry J Allen; Eva Bezak; Loredana G Marcu
Journal:  Biomed Res Int       Date:  2013-05-16       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.